论文部分内容阅读
[目的]对比分析奈达铂联合培美曲塞、多西他赛治疗晚期非小细胞肺癌的疗效,以及对患者血清可溶性细胞间黏附分子(s ICAM-1)、可溶性血管细胞黏附分子(s VCAM-1)的影响。[方法]选择2013年3月至2016年2月收治的89例非小细胞肺癌患者,分为培美曲塞组45例和多西他赛组44例。比较两组患者临床疗效、血清肿瘤标志物、s ICAM-1、s VCAM-1水平及不良反应发生情况。[结果]培美曲塞组的总有效率为21.6%(10/45),而多西他赛组的总有效率为17.6%(8/44),两组患者的临床总有效率无统计学差异(χ~2=0.225,P=0.793);两组患者的CEA、CYFRA21-1水平均较化疗前显著性下降(P<0.05),然而培美曲塞组和多西他赛组之间并无显著性差异(P>0.05);两组患者s ICAM-1、s VCAM-1水平均较化疗前显著性下降(P<0.05)。培美曲塞组白细胞减少、贫血、脱发等不良反应的发生率显著性低于多西他赛组。[结论]奈达铂联合培美曲塞与奈达铂联合多西他赛在治疗晚期非小细胞肺癌的总有效率上无统计学差异,然而奈达铂联合培美曲塞组不良反应较轻,值得临床推广。
[Objective] To compare the curative effect of nedaplatin combined with pemetrexed and docetaxel in the treatment of advanced non-small cell lung cancer, as well as the clinical significance of serum soluble intercellular adhesion molecule (s ICAM-1), soluble vascular cell adhesion molecule VCAM-1). [Methods] A total of 89 patients with non-small cell lung cancer who were admitted to our hospital from March 2013 to February 2016 were divided into pemetrexed group (n = 45) and docetaxel group (n = 44). The clinical efficacy, serum tumor markers, s ICAM-1, s VCAM-1 levels and adverse reactions in the two groups were compared. [Results] The total effective rate of pemetrexed group was 21.6% (10/45), while the total effective rate of docetaxel group was 17.6% (8/44). The total clinical effective rate was no statistical difference between the two groups (Χ ~ 2 = 0.225, P = 0.793). The levels of CEA and CYFRA21-1 in both groups were significantly lower than those before chemotherapy (P <0.05), however, pemetrexed group and docetaxel group (P> 0.05). The levels of s ICAM-1 and s VCAM-1 in both groups were significantly lower than those before chemotherapy (P <0.05). Pemetrexed group leukopenia, anemia, hair loss and other adverse reactions was significantly lower than docetaxel group. [Conclusion] There is no significant difference in the total effective rate between nedaplatin combined with pemetrexed and nedaplatin combined with docetaxel in the treatment of advanced non-small cell lung cancer. However, the adverse reactions of nedaplatin combined with pemetrexed group are not statistically significant Light, worthy of clinical promotion.